Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up. - Wikidata - awgldk - TriplyDB

Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.

Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.

http://www.wikidata.org/entity/Q30495509

about

Targeted exercise therapy for voice and swallow in persons with Parkinson's disease Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes Comparison of speech and language therapy techniques for speech problems in Parkinson's disease Common movement disorders affecting the larynx: a report from the neurolaryngology committee of the AAO-HNS Translating principles of neural plasticity into research on speech motor control recovery and rehabilitation.Self-perception of speech changes in patients with Parkinson's disease following deep brain stimulation of the subthalamic nucleus Clear Speech Variants: An Acoustic Study in Parkinson's Disease.The Role of Rhythm in Speech and Language Rehabilitation: The SEP Hypothesis Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.Exercise Effects on Early Vocal Ultrasonic Communication Dysfunction in a PINK1 Knockout Model of Parkinson's Disease Listener Perception of Monopitch, Naturalness, and Intelligibility for Speakers With Parkinson's Disease.A retrospective study of long-term treatment outcomes for reduced vocal intensity in hypokinetic dysarthria Speech-related fatigue and fatigability in Parkinson's disease The Therapeutic Effects of Singing in Neurological Disorders.The effect of increased vocal intensity on interarticulator timing in speakers with Parkinson’s disease: a preliminary analysis Subjective Experiences of Speech and Language Therapy in Patients with Parkinson's Disease: A Pilot Study.Early identification and treatment of communication and swallowing deficits in Parkinson disease.Speech-Breathing Treatment and LSVT for a Patient With Hypokinetic-Spastic Dysarthria After TBI.Telerehabilitation, virtual therapists, and acquired neurologic speech and language disorders Basic parameters of articulatory movements and acoustics in individuals with Parkinson's disease.Effect of level of presentation to listeners on scaled speech intelligibility of speakers with dysarthria Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease.Effects of loudness cues on respiration in individuals with Parkinson's disease.Changes to articulatory kinematics in response to loudness cues in individuals with Parkinson's disease.Age-related changes to speech breathing with increased vocal loudness.LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease.Voice disorders in children with classic galactosemia.A cognitive-perceptual approach to conceptualizing speech intelligibility deficits and remediation practice in hypokinetic dysarthria Effect of LSVT on Lexical Tone in Speakers with Parkinson's Disease.A translational approach to vocalization deficits and neural recovery after behavioral treatment in Parkinson disease.Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.The somatotopy of speech: phonation and articulation in the human motor cortex Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats Limb use and complex ultrasonic vocalization in a rat model of Parkinson's disease: deficit-targeted training.Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study.Rehabilitation for Parkinson's disease: a systematic review of available evidence.Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease.

P2860

Q22252333-5C92E877-8D8C-4E77-9941-1D3061181E33 Q24193064-046DBCFB-A47B-49F8-AD17-4348CB5D0AF9 Q24201335-37F81E07-6842-46AC-B405-4FA47C5CFB83 Q28280828-7B06DCD1-62F5-4454-B639-72552916058E Q28754738-72CEDE62-B57A-4F25-B705-B8031EAF2D2C Q29041414-43151C46-80B5-4E75-A318-300DD130D359 Q30364587-06AD66D2-A099-4946-BF02-0036028DA3A4 Q30368215-426769DF-918F-413C-879D-409857C6CE60 Q30380046-B6F0F289-880A-4084-9544-3559D3CF085B Q30383666-1F8192E1-392D-4F96-BDD4-1450F348C801 Q30390464-B86A08EF-FD97-4AF2-B942-0E9D2A224FD5 Q30391797-3833BAAE-E419-40D4-A666-9F14907E30D3 Q30394653-3A0B1CD1-42DF-45F3-9132-52804858ACA6 Q30397326-012CBC16-866C-4647-B5E5-7D1BFF25AF81 Q30399877-FAF5D8BC-F4D1-4778-A33A-101495B6C357 Q30405571-A800FDB8-9665-4026-A3C8-D0D66526287E Q30408790-CE8DF1A0-67EC-4519-95D6-44A73E3C7436 Q30450924-05C86811-C1EC-4A03-9E7D-2D9C941BD9FF Q30453271-B03E5CE2-D884-4A4E-86DB-E37EA6532102 Q30454131-B1548299-F6AB-4D5F-952E-BD0B2F8CE7DA Q30460259-6BC35656-BEE9-4114-B3CC-9FA371670174 Q30461883-740A5B51-0C07-484C-A997-38C7A553343A Q30461934-761EB337-68A0-411D-976C-DD5B4C98622F Q30463629-0E3791CF-F8B9-4575-81A7-F3E457B62772 Q30463962-4AF85CB8-91E7-4CA1-802E-0214600CB822 Q30463964-B3B98F5A-4BEC-4189-BB0B-EE46D0583842 Q30468357-271C28F0-6CF4-4E34-BB58-3A8D71457732 Q30469056-15BCCB1C-285F-4857-99A2-480E8C11E637 Q30474147-47B9876B-E023-4A8A-8607-82E012363552 Q30474426-00C47B55-2DD1-45DE-8EB0-D3EB9CAC8715 Q30474950-036DDE87-19DB-4472-911C-87192936A291 Q30477266-27E657FF-4F2C-4D91-9ABD-DD51F6628DAF Q30481436-E555A7E9-7A0A-4FE3-B015-D976699E8714 Q30482259-143C4025-1A95-4F59-A0C8-D26BACF6BE70 Q30487022-434A2B83-221C-4311-8720-F9A182B6AA4A Q30493550-985FF542-927B-437A-8C9F-F7DDD7B76C7F Q31104672-8D0675BD-AB79-4FDE-B071-FA9C104BBD62 Q33761045-4DCD7D0F-DC74-43C2-920B-F5266B312EBD Q34166797-9485B734-436B-40FD-9798-17E6E9394C8A Q34281936-16973057-BABD-4ECB-A316-FC185251037B

P2860

Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.

http://www.wikidata.org/entity/Q30495509

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@ast

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@en

type

label

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@ast

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@en

prefLabel

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@ast

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@en

P1433

Q30495509-3275D73E-5B70-43EF-AC5D-D45AEE99E5F6

P1476

Q30495509-EA49379C-1E85-4BB3-9C2A-DA169DE4929A

P2093

Q30495509-271C37C1-5D95-4794-9F51-8D1924C11E99

Q30495509-40361961-CB08-45C8-86C0-E199E649A3CC

Q30495509-6B0F6874-DE80-4EA9-AAFC-5B15EFF45E1A

Q30495509-8DF80564-735B-4F38-BC17-45140909F523

Q30495509-DE3665EE-8AED-4203-BD95-BEA21EC1B46E

Q30495509-E6FA4E69-30B5-4DE5-8EA8-C2BF22AC6425

Q30495509-EA192F15-522F-4D61-A948-E6016D0B52ED

P2860

Q30495509-088AA5A0-6206-49FD-B9E8-0AADA174E3C2

Q30495509-0A3C292E-6C09-468F-B8C2-4423F7C278B0

Q30495509-10F331F3-3687-42F9-9016-3FB015998D4C

Q30495509-12B911E9-C9D0-4AA1-BA0E-9C6E08419C1F

Q30495509-221F3E6A-E7EE-460A-9A5C-F7491964FB80

Q30495509-543A49AA-08A0-4BA4-BE3F-A6F8BD85F25B

Q30495509-59F3954B-EEA0-4249-B2CE-463940991943

Q30495509-5BB0389A-ADCD-47C3-8150-CAB4EBC35391

Q30495509-6978A0C2-1D74-45EE-A023-EBD73A0DC8FE

Q30495509-6A353969-6717-4D59-ADFC-4C182C05C9D6

P304

Q30495509-03665B47-725E-43E8-B843-B8B8FBECF225

P31

Q30495509-8D24B4F1-4986-424A-96FB-B433EFA0E4BC

P356

Q30495509-A8E0CC32-091D-4AB1-A859-A46F35C04BD0

P407

Q30495509-0FF79A4F-FE9B-4752-944B-CA75529F549F

P433

Q30495509-E1320AEB-F5B8-4E9C-A443-DED8991B6062

P478

Q30495509-A465A222-A4B7-47CE-88A2-CE18CBA56DE4

P577

Q30495509-49BE0EB2-8C39-4291-B929-575369BC9714

P5875

Q30495509-E96C5D4E-EE9F-4A80-92A1-A35E5C49DCAC

P698

Q30495509-0783CC4A-CA91-4DF4-80E1-AFEC8FB6A01E

P921

Q30495509-C85BFFC5-1BA1-4638-8EBD-FED6A37D7710

P932

Q30495509-6A0C0076-9E3F-4750-8A77-D8CA166676DC

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Intensive voice treatment (LSV ...... s disease: a 2 year follow up.

@en

P2093

A A Pawlas

http://www.w3.org/2001/XMLSchema#string

C O'Brien

http://www.w3.org/2001/XMLSchema#string

L L Thompson

http://www.w3.org/2001/XMLSchema#string

L O Ramig

http://www.w3.org/2001/XMLSchema#string

M Hoehn

http://www.w3.org/2001/XMLSchema#string

S Countryman

http://www.w3.org/2001/XMLSchema#string

S Sapir

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinsonism: onset, progression and mortality

Effect of practice on performance of a skilled motor task in patients with Parkinson's disease.

Speech therapy for Parkinson's disease

Ability to modulate walking cadence remains intact in Parkinson's disease.

Speech therapy and Parkinson's disease: a review and further data.

Cognitive impairments in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes.

The Parkinson larynx: tremor and videostroboscopic findings.

Parkinson's disease and nonpharmacologic treatment programs.

Motor training in the therapy of Parkinson's disease.

Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation.

P304

493-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.71.4.493

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11787020

http://www.w3.org/2001/XMLSchema#string

P698

11561033

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

1763504

http://www.w3.org/2001/XMLSchema#string